Navigation Links
OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals
Date:9/6/2011

BOTHELL, Wash. and VANCOUVER, British Columbia, Sept. 6, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that data from two studies, a Phase II clinical study and a pre-clinical study, evaluating the investigational compound custirsen (OGX-011/TV-1011), were published in the September issues of the journals Clinical Cancer Research and Cancer Research.

Custirsen inhibits the production of clusterin, a protein commonly over-produced in cancer cells and a cause of treatment resistance. Two Phase III studies evaluating custirsen in men with castrate-resistant prostate cancer (CRPC) are ongoing: the SYNERGY clinical trial - designed to evaluate an overall survival benefit for custirsen in combination with first-line docetaxel treatment, and the Prostate Cancer SATURN Trial - which will evaluate a durable pain palliation benefit in patients receiving second-line chemotherapy. Both studies are currently enrolling CRPC patients.

Phase II Data Published in Clinical Cancer Research

Data from a Phase II clinical study of custirsen in combination with docetaxel retreatment or mitoxantrone as second-line chemotherapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) was published in the September 1, 2011 issue of Clinical Cancer Research.

In the clinical study, custirsen combined with docetaxel retreatment resulted in overall survival of 15.8 months. When custirsen was combined with mitoxantrone, overall survival was 11.5 months. The Phase II study also evaluated pain responses in patients with mCRPC. Overall, the pain response was durable (greater than or equal to three months) in 88 percent of patients who had pain or were on opioids for pain at study entry.

"These are encouraging results because we observed durable pain responses in many patients who had di
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer
2. OncoGenex Reports Third Quarter Financial Results
3. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
4. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
5. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
6. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
7. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
8. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
9. OncoGenex Reports Second Quarter Financial Results
10. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
11. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... CannLabs, Inc. (OTCQB: CANL), the leading ... methodologies relating to cannabis, today announced that it has ... from an existing stockholder of the Company. , ... from one of our existing stockholders,” stated Mark ... help accelerate our planned expansions into the Connecticut and ...
(Date:11/22/2014)... November 21, 2014 On November 17th ... the 2014 Emerging Medical Technologies Summit in San Francisco ... Widely regarded among Silicon Valley investors and technology ... innovation, the win also positions Briteseed to move ... competition in 2015 and compete with other elite innovation ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Respiratory ... simulate the proper management of life-like respiratory ailments ... lung devices . Grand Rapids-based, Michigan Instruments Inc. ... donate two of the respiratory simulation units to ... each. Grand Valley and Muskegon Community College are ...
(Date:11/22/2014)... 21, 2014   ... Commercial Officer zu KLOX    ... Chief Financial Officer bestellt    KLOX ... seines jüngst zugelassenen Behandlungssystems zur Wundheilung zu beginnen    ... "Unternehmen") ist sehr erfreut, die folgenden personellen Veränderungen anzukündigen: ...
Breaking Biology Technology:CannLabs Secures $750,000 Line Of Credit 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5
... Iowa, Dec. 18 - DuPont today congratulated,growers planting ... of,the 15 national categories in the 2007 National ... these growers won with Pioneer sorghum,hybrid 84G62., ... in all,five national contest segments. First-, second- and ...
... PALO ALTO, Calif., Dec. 18 CV Therapeutics,Inc. ... U.S. Food and Drug,Administration (FDA) has approved new ... tablets) which describes the ability,of ranolazine to inhibit ... Published data on ranolazine,s mechanism suggests that during ...
... Md., Dec. 18 Panacea Pharmaceuticals, lung,cancer ... one of Time Magazine,s,Ten Biggest Medical Breakthroughs ... please cut,and paste into browser:, http://www.time.com/time/specials/2007/top10/article/0,30583,1686204_1686252_1690390, ,00.html) ... to facilitate the identification,of lung cancer, even ...
Cached Biology Technology:DuPont Congratulates Growers Planting Pioneer(R) Brand Sorghum Hybrids in Winning Majority of National Categories in Yield Contest 2FDA Approves New Mechanism of Action Labeling for Ranexa(R) 2Panacea Pharmaceuticals' Lung Cancer Diagnostic Test, LC Detect(SM), Named One of Time Magazine's Ten Biggest Medical Breakthroughs of 2007 2Panacea Pharmaceuticals' Lung Cancer Diagnostic Test, LC Detect(SM), Named One of Time Magazine's Ten Biggest Medical Breakthroughs of 2007 3Panacea Pharmaceuticals' Lung Cancer Diagnostic Test, LC Detect(SM), Named One of Time Magazine's Ten Biggest Medical Breakthroughs of 2007 4
(Date:11/10/2014)... pods began appearing on U.S. store shelves in early ... ever since. The small packets can be tossed into ... a liquid or powder. The convenience, though, has come ... from researchers at Nationwide Children,s Hospital found that from ... of 17,230 children younger than 6 years of age ...
(Date:11/6/2014)... yet progress in preventing and treating migratory cancer ... challenging to design drugs that work against metastasis," ... at Harvard Medical School. , "Unfortunately, many ... , Gujral and colleagues have now identified a ... how metastasis begins. Their findings may also inform ...
(Date:11/5/2014)... de Janeiro, Brazil -Individuals show great diversity in their ... males and females greatly differ in their perceptual evaluation ... of smell tests. , Sex differences in ... behaviors and may be connected to one,s perception of ... emotions. Thus, women,s olfactory superiority has been suggested to ...
Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Migration negation 2Migration negation 3The female nose always knows: Do women have more olfactory neurons? 2
... "It,s in their genes" is a common refrain from ... age 100 and beyond. Up until now, research has ... as high levels of HDL ("good") cholesterol. But researchers at ... Graduate School of Psychology of Yeshiva University have found ...
... have discovered that some hardy species can survive the ... submersible rises to the surface. The team,s findings, published ... can be inadvertently carried by submersibles to new areas, ... using the manned submersible Alvin to collect samples of ...
... DURHAM, N.C. Women receiving care for breast ... for years after they have completed treatment, according to ... Center. The findings, reported online in the ... that poor cardio-pulmonary function may be a strong predictor ...
Cached Biology News:'Personality genes' may help account for longevity 2Deep sea animals stowaway on submarines and reach new territory 2Cardio fitness levels of breast cancer patients may affect survival 2
... The standard electrophoresis hood ... gel documentation systems. Placed on ... camera in place and provides ... photography on the lab bench. ...
... microarrays are derived from frozen embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5 mm in ...
... derived from Paraffin embedded tissue blocks, which ... to ensure the highest quality. Tissues of ... block, sectioned at a thickness of 5 ... are large (3-5 mm in diameter) in ...
... tissue microarrays are derived from Paraffin embedded ... quality control procedures to ensure the highest ... assembled in one block, sectioned at a ... coated slides. Sections are large (3-5mm in ...
Biology Products: